Background and objective: The Glasgow prognostic score (GPS) reflects the host systemic inflammatory response and is a validated independent prognostic factor in lung cancer. We investigated GPS as a potential predictive factor of clinical outcomes in idiopathic pulmonary fibrosis (IPF) patients with acute exacerbation (AE). Methods: This was a retrospective study performed between January 2006 and March 2016 in Bucheon St. Mary's Hospital, The Catholic University of Korea. Overall, 327 admitted IPF patients were registered in the study. Patients with definite pneumonia at the time of admission, those with left-sided heart failure, pulmonary embolism and an identifiable cause of acute lung injury, and those whose albumin or C-reactive protein levels were not measured were excluded. Results: A total of 66 patients hospitalized with IPF-AE were finally included. Median survival was 20.7 days and 29 (43.9%) patients died during hospitalization. The median length of overall survival (OS) was 26.0, 20.0 and 15.0 days for GPS-0, GPS-1 and GPS-2, respectively. There were significant differences in OS between GPS-0 and GPS-2 (P = 0.002). In a multivariate analysis performed using a Cox regression model, eosinopenia (P = 0.007), lower partial pressure of oxygen/fraction of inspired oxygen ratio (P = 0.014), and higher GPS (P = 0.006) were independent predictors of mortality. Conclusion: GPS can be helpful in predicting mortality in IPF patients with AE.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) characterized by worsening lung function and poor prognosis. Acute exacerbations (AEs) of IPF are associated with substantial morbidity and mortality. 1 The aetiology of AEs of IPF are not precisely known. Acceleration of the underlying fibrotic disease, unrecognized infection, diffuse alveolar damage caused by the gastro-oesophageal reflux, and acute direct stress to the lungs have all been suggested to explain IPF-AE. 2 The role of inflammation in IPF remains controversial. Some evidence has shown that inflammation is not required for the development of a fibrotic response. 3, 4 Lack of a correlation between clinical outcome and severity of inflammation and poor response to antiinflammatory therapy such as glucocorticoids in patients with IPF support this idea. [5] [6] [7] On the other hand, there is some evidence that inflammation is involved in IPF. Serum albumin, a negative acute-phase protein used as a marker of inflammation, was independently associated with a higher transplant waiting list mortality rate in patients with IPF. 8 Also, C-reactive protein (CRP) level was found to be a determinant of 3-month survival and in-hospital mortality in participants of IPF-AE.
SUMMARY AT A GLANCE
The present study is one of the first studies to investigate the Glasgow prognostic score (GPS) as a potential predictive factor of clinical outcomes in patients with idiopathic pulmonary fibrosis, who experience acute exacerbation requiring hospital admission. Higher GPS, eosinopenia and partial pressure of oxygen/fraction of inspired oxygen ratio were independent predictors of mortality.
The Glasgow prognostic score (GPS) is an inflammation-based prognostic scoring system that is based on albumin and CRP levels. Recent studies have shown that GPS may reliably represent prognostic factors in patients with various malignancies including lung, nasopharyngeal and oesophageal cancer. [11] [12] [13] [14] [15] [16] However, the prognostic value of GPS in IPF-AE has never been investigated. In the present study, therefore, we evaluated the clinical significance of GPS in IPF-AE patients requiring hospital admission. 
METHODS

Patients
Our institution has an ILD cohort and maintains clinical and laboratory data of these patients which were collected prospectively using an ILD-specified protocol. Our ILD cohort consisted of 533 patients between January 2006 and March 2013. Of this cohort, 327 (86 confirmed by surgical lung biopsy) were IPF patients previously diagnosed according to international consensus statements. 17, 18 Of these, 66 patients who were hospitalized with IPF-AE, were included in our analysis. For the validation of correct diagnosis, individual chart review and correlation with the International Classification of Diseases (ICD) version 10 codes was performed. Patients with congestive heart failure (CHF), those who exhibited definite pneumonic infiltrations on chest X-ray at the time of admission, those who were admitted for treatment of other medical problems, those who transferred to other medical centres, those who were admitted for the base study such as surgical lung biopsies to confirm diagnosis or bronchoalveolar lavage (BAL) to rule out differential diagnosis, and those who did not have their albumin or CRP levels measured were excluded. Only the most recent hospitalization event was considered for each patient. The study flow is summarized in Figure 1 .
Definition
The criteria for IPF-AE include an unexplained worsening of dyspnoea within 1 month, evidence of hypoxia as defined by worsened or severely impaired gas exchange, new radiographical alveolar infiltrates and the absence of an alternative explanation such as infection, pulmonary embolism, pneumothorax or CHF. 17 Treatment strategy was classified as follows: low-dose steroid, ≤ 0.5 mg/kg/day prednisolone; high-dose steroid, > 0.5 mg/kg/day prednisolone; and pulse therapy, 500-1000 mg/day methylprednisolone. All patients were categorized into three groups based on the GPS score as follows: GPS of 2: elevated CRP (>1.0 mg/dL) and hypoalbuminemia (<3.5 g/dL); GPS of 1: elevated CRP or hypoalbuminemia; GPS of 0: neither elevated CRP nor hypoalbuminemia. 19, 20 Overall survival (OS) was defined as the time from the date of admission to the date of death by any cause.
Data
We extracted the following data from medical records: patient demographics; body mass index (BMI); smoking history; types of regular medications taken; laboratory data (including those pertaining to arterial blood gas analysis , albumin and CRP levels); pulmonary function test (PFT) results; BAL results; days in hospital; and treatment results. PFT and BAL were not performed in patients with IPF-AE, these data were from an assessment of the stable state of patients.
Treatment regimens for IPF-AE include the use of high-dose or low-dose corticosteroids with or without immunosuppressive agents and broad-spectrum antibiotics despite a lack of convincing evidence demonstrating a benefit thereof. Prescription of antibiotics and systemic steroids was given at the discretion of attending clinicians.
Based on GPS criteria, all IPF patients were classified into three groups. Clinical parameters and the inhospital mortality rate were compared among the three groups.
Statistical analysis
Baseline demographics and clinical outcomes were compared among patients according to GPS criteria. We used Pearson's chi-square test to compare discrete variables and Student's t-test or analysis of variance (ANOVA) to compare continuous variables. KaplanMeier univariate analysis for categorical variables and univariate Cox proportional hazards regression for continuous variables were used to analyse the impact of possible predictors on survival rate. Hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were calculated for predictors that were significant in the multivariate analysis. A two-sided P-value < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS for Windows software (ver. 20.0; IBM Corp., Armonk, NY, USA). 
RESULTS
Overall, 327 IPF patients were admitted to the hospital over the study period, of whom 261 met the exclusion criteria of definite pneumonia at the time of admission, admission for other medical problems, presence of CHF, transfer to another medical centre, lack of measurement of albumin or CRP levels, or admission for the base study. A total of 66 patients were finally included in our analysis. Of these patients, 32 (48.5%), 21 (31.8%) and 13 (19.7%) patients were classified into the GPS 0, GPS 1 and GPS 2 groups, respectively. We explored the factors that predicted survival and compared patients according to their GPS.
The clinical characteristics of survivors and nonsurvivors were compared. A total of 29 (43.93%) IPF-AE patients died. Forced vital capacity (FVC) was lower and the proportion of fever at the time of admission was higher in the non-survivor group (P = 0.035 and P = 0.009, respectively). Other baseline characteristics, including age, gender, BMI, history of smoking and duration of dyspnoea, did not differ significantly between survivors and non-survivors. BAL fluid analysis performed in a stable state and types of regular medications prescribed at outpatient clinics were similar between the two groups ( Table 1 ).
In the laboratory findings taken on admission, nonsurvivors had lower pH levels and higher lactate dehydrogenase (LDH) levels than survivors. Partial pressure of oxygen/fraction of inspired oxygen (P/F) ratio and albumin and CRP levels were not different between the survivor and non-survivor groups (Table 2 ). In terms of treatment strategies for IPF-AE, steroids combined with antibiotics (P = 0.006) was more common in the nonsurvivor group, and steroid-only (P = 0.039) use was more common in the survivor group. In patients treated with therapy including steroids, the survival rate was not different according to dose of steroid given (Table 3) .
Baseline characteristics of each GPS group and comparisons between groups are depicted in Table 4 . The LDH level and white blood cell (WBC) count were lower in the GPS 0 group (P = 0.005 and P = 0.018, respectively). Age, P/F ratio and pro-BNP (pro-brain type natriuretic peptide) level were not different among the three groups (Table 4) .
In an analysis of the prognostic factors for survival, various potential prognostic factors including age, fever, eosinopenia, LDH level, P/F ratio, FVC and GPS were analysed. Univariate analysis revealed that fever (P = 0.038), eosinopenia (P = 0.005), and GPS 2 (P = 0.002) were poor prognostic factors for survival. In the multivariate analysis, eosinopenia (OR (odds ratio) 4.184, 95% CI: 1.476-11.859; P = 0.007), P/F ratio (OR 0.988, 95% CI: 0.979-0.998; P = 0.014), and higher GPS (OR 7.799, 95% CI: 1.816-33.499; P = 0.006) were independent prognostic factors for survival (Table 5 ). Survival curves grouped by GPS are shown in Figure 2 . The median OS of all patients was 20.7 days, and it was 26.0, 20.0 and 15.0 days for patients with GPS 0, 1 and 2, respectively. 
DISCUSSION
We compared the clinical characteristics and treatment outcomes of IPF-AE based on GPS. In the present study, the in-hospital mortality rate of IPF-AE patients was 43.9%. Based on the level of albumin and CRP, IPF-AE patients were categorized into GPS 0, 1 and 2 groups. Patients with GPS 2 had a higher in-hospital mortality rate than did those with GPS 0.
One possible explanation for the association between poor prognosis and higher GPS is that inflammation plays an important role in IPF-AE. 21, 22 It is unclear whether IPF-AE is indicative of a primary acceleration of the underlying fibrotic process or a secondary complication due to clinical triggers such as infection or environmental factors. The established risk factors for IPF-AE are IPF severity based on low FVC, 10, 23, 24 thoracic surgical procedures, 25,26 dyspnoea scale, 23 and absence of smoking history. 10 The role of inflammation in the pathogenesis of IPF is controversial. The notion that inflammation has no role in pulmonary fibrosis is based on the poor response of patients to conventional anti-inflammatory therapy. 6, 7, 27 Inflammation is not a common, prominent pathological finding in participants of interstitial pneumonia, even in the early stages of IPF. 28 In addition, an inflammatory response to a lung fibrogenic insult is not necessary to induce a fibrotic response. 3 Selman et al. suggest that IPF involves abnormal wound healing in response to multiple alveolar epithelial injury in the absence of adequate reepithelialization. 29 However, IPF-AE is frequently accompanied by fever, cough and myalgia, suggesting infection or systemic inflammation. In our study, 9.1% of patients had fevers and the proportion of those with fevers was higher in the non-survivor group. Viral infections such as infections with Epstein-Barr virus or herpesvirus have been suggested to induce an immune response resulting in lung fibrosis. 30, 31 Several clinical studies have suggested that acute worsening of IPF may result from diverse viral infections in an immune-mediated manner, although these results are controversial. [32] [33] [34] An increased bacterial burden in the BAL of IPF patients predicts a decline in lung function and death. 35, 36 Also, chronic airway inflammation is associated with phenotypic modulation of lung fibroblasts to myofibroblasts. 37 These findings suggest the possibility that IPF-AE may be associated with inflammation with or without undiagnosed infection.
In previous clinical studies, CRP levels were a significant prognostic factor of IPF-AE, suggesting that inflammation may be involved in the pathogenesis of AE. 9, 10, 38 Lower levels of serum albumin, a negative acute-phase protein and marker of inflammation, were strongly and independently associated with higher mortality in patients with IPF on transplant waiting lists. 8 Factors known to be associated with poor prognosis in IPF-AE are combined diffuse and multifocal patterns rather than peripheral patterns on high- Table 4 Association of GPS with patient characteristics Characteristics GPS = 0 (n = 32) GPS = 1 (n = 21) GPS = 2 (n = 13) P-value DLco, diffusing capacity of the lung for carbon monoxide; FEV 1 , forced expiratory volume in 1 s ; FVC, forced vital capacity; GPS, Glasgow prognostic score; LDH, lactate dehydrogenase; P/F, partial pressure of oxygen/fraction of inspired oxygen; PFT, pulmonary function test; Pro-BNP, pro-brain type natriuretic peptide; RV, residual volume; TLC, total lung capacity; WBC, white blood cell.
resolution computed tomography (HRCT), age at onset of IPF, and higher CRP levels. 10, 39, 40 GPS is an inflammation-based prognostic score that consists of albumin and CRP levels. GPS has been shown to be useful for prognosis in various cancers. 12, 14, 16 However, to our knowledge, the role of GPS in IPF-AE has not been previously examined.
In our study, eosinopenia was one of the poor prognostic factors in IPF-AE. Eosinophils are involved in many disease processes, such as infection, asthma and gastrointestinal disorders. 41 Eosinopenia is known to be associated with acute infection and inflammation. Eosinopenia in acute infection has been attributed to adrenal glucocorticosteroid production triggered by the stress of the infection. During the acute stage of inflammation, rapid peripheral sequestration and migration of circulating eosinophils to the site of infection by cytokines and chemotactic substances results in eosinopenia. 42 Clinically, eosinopenia has been suggested to be a prognostic marker for critically ill patients admitted to the Intensive Care Unit and those with COPD AE. [43] [44] [45] Both higher GPS and eosinopenia are representative of acute inflammation, and these factors were related with poor clinical outcomes in patients with IPF-AE in our study. Based on this finding, we suggest that inflammatory exacerbations of IPF are related to poor clinical outcomes.
Our study had certain limitations. First, this is a retrospective single centre study. Not every patient was given a complete medical work-up for identifying other causes that result in acute worsening of IPF, including echocardiography and pulmonary thromboembolism (PTE) computed tomography (CT), to rule out congestive heart failure or PTE. Also, diagnostic discrimination between atypical pneumonia such as viral infection or Pneumocystis jiroveci and idiopathic exacerbation of IPF-AE was not comprehensively performed. Nonetheless, we consecutively enrolled every patient with IPF-AE starting in January 2006 and collected medical records using a consistent protocol as completely as possible. Second, IPF-AE management was not identical in all patients. The rate of use of steroid pulse therapy was higher in non-survivors and low-dose steroid use was more common in survivors. Prescriptions for steroids were given at the discretion of pulmonologists. Third, the proportion of lymphocytosis (>30%) in the cellular analysis of BAL was about 40% in our study. BAL lymphocytosis is uncommon and it suggests considering other diagnoses such as connective tissue disease (CTD)-related ILD or hypersensitivity pneumonitis. This raises concerns that the study population may include non-IPF patients. Of 66 patients enrolled, BAL was performed in 22 patients in a stable state and 9 demonstrated lymphocytosis in BAL findings. All nine patients demonstrated consistent UIP pattern on the chest CT findings with exclusion of CTD-ILD on the basis of screening for autoimmune markers. Three of these had usual interstitial pneumonia (UIP) confirmed by surgical biopsy. Fourth, we included only patients with an 'idiopathic' IPF-AE as per the classic definition. Therefore, the clinical relevance of our results for participants with IPF-AE as defined by the recently updated definition of an acute respiratory worsening and diffuse alveolar damage of any aetiology is not known. 46 Finally, the association of incremental GPS with mortality in IPF-AE patients could be explained by unassessed confounding factors. A prospective study is needed to clarify the prognostic value of GPS in patients with IPF-AE.
Despite these limitations, our research had several strengths. First, although several studies exploring prognostic factors in IPF-AE patients requiring hospital admission have been published, the prognostic value of GPS has not been previously investigated in patients with IPF-AE. Our work suggests that higher GPS on admission is a poor prognostic factor. GPS is a simple, easy to check and reliable marker of inflammatory activity, and this information could help clinicians to predict clinical course of IPF in patients hospitalized with severe exacerbation.
In conclusion, higher GPS, P/F ratio and eosinopenia were identified as prognostic factors for poor outcome in participants of IPF-AE. Further prospective studies with consistent approaches to treatment are needed to clarify the utility of GPS in patients with IPF-AE.
